KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Change in Receivables (2017 - 2025)

Historic Change in Receivables for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to -$6.8 million.

  • Twist Bioscience's Change in Receivables fell 25045.18% to -$6.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.0 million, marking a year-over-year increase of 16545.41%. This contributed to the annual value of $22.4 million for FY2025, which is 36506.4% up from last year.
  • Per Twist Bioscience's latest filing, its Change in Receivables stood at -$6.8 million for Q4 2025, which was down 25045.18% from $7.2 million recorded in Q3 2025.
  • In the past 5 years, Twist Bioscience's Change in Receivables registered a high of $10.7 million during Q1 2025, and its lowest value of -$8.1 million during Q4 2023.
  • Moreover, its 5-year median value for Change in Receivables was $1.8 million (2022), whereas its average is $1.2 million.
  • Per our database at Business Quant, Twist Bioscience's Change in Receivables crashed by 32827.59% in 2022 and then surged by 153196.35% in 2025.
  • Over the past 5 years, Twist Bioscience's Change in Receivables (Quarter) stood at $2.0 million in 2021, then soared by 101.67% to $4.1 million in 2022, then tumbled by 296.63% to -$8.1 million in 2023, then skyrocketed by 156.3% to $4.5 million in 2024, then plummeted by 250.45% to -$6.8 million in 2025.
  • Its Change in Receivables stands at -$6.8 million for Q4 2025, versus $7.2 million for Q3 2025 and -$87000.0 for Q2 2025.